Search Results
116 Results Found for “minimal residual disease ”
Circulating tumor DNA (ctDNA) has emerged as an innovative and minimally invasive tool in precision oncology. With a short half-life of 30–120 min, ctDNA provides real-time insight into tumor dynamics.1 In early-stage breast cancer, there is growing evidence supporting its potential ...
At EBCC15, Dr Elisa Agostinetto presented compelling evidence that circulating tumor DNA (ctDNA) at completion of neoadjuvant therapy could be a game-changer biomarker for predicting breast cancer relapse. In the Q&A below, Dr. Agostinetto discusses the implications of her findings and the path toward integrating ctDNA into routine clinical practice.
2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, ESMO, EHA, ASH and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.
With the second half of 2025 underway, we asked our touchONCOLOGY Future Leaders 2025 to share the developments they believe will shape the future of the field. Here, they highlight five exciting areas that promise to transform practice – not only as the year draws to a close, but well into the future.
The first half of 2025 has brought exciting developments in oncology, with groundbreaking research and real-world progress showcased at ASCO, EHA and many more leading conferences around the world. We asked five of our touchONCOLOGY Future Leaders 2025 to share what they believe has been most impactful so far this year – here’s what they told us.
Liquid biopsy: Initial concepts and application in solid tumours The US National Cancer Institute defines liquid biopsy (LB) as ‘a test done on a sample of blood to look for cancer cells from a tumour that are circulating in the ...
Acute myeloid leukaemia (AML) is a heterogeneous haematologic cancer associated with clonal expansion of myeloid blasts in the bloodstream, bone marrow and other tissues. AML is associated with blasts expressing various complex molecular and cytogenetic alterations, which play an important ...
Breast cancer is the leading cause of cancer death in Hispanic women in the USA. According to the American Cancer Society, as many as one in nine Hispanic women will develop invasive breast cancer during their lifetime and one in 49 ...
Each year, the EHA Board presents the José Carreras Award to honour leaders in haematological research. touchONCOLOGY caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss his receipt of the José Carreras Award and the key take-home ...
The phase III MURANO trial (NCT02005471) reported that venetoclax plus rituximab (venR) resulted in higher progression-free survival and overall survival than bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia. The unmet needs in the treatment of chronic ...
Multiple myeloma (MM) is the second most common haematological malignancy, with upwards of 35,000 diagnoses in the USA each year.1,2 It remains a leading cause of blood cancer-related mortality worldwide, and although therapeutic advances have allowed for significant improvements in the ...
Head and neck squamous cell carcinomas (HNSCCs) encompass a diverse group of tumours arising from the nasopharynx, oral cavity, oropharynx, hypopharynx and larynx. Tobacco and alcohol abuse are risk factors for the development of HNSCC, particularly oral cavity, hypopharyngeal and ...
Welcome to the latest edition of touchREVIEWS in Oncology & Haematology. Despite the success of the human papillomavirus vaccination programme, cervical cancer remains one of the most common cancers in women, and advanced disease carries a poor prognosis. Lebreton et ...
To date, the cornerstone of curative treatment in early-stage gastrointestinal (GI) cancers includes surgery and sometimes radiation therapy. Depending on the stage and tumour type, these approaches are often combined with systemic neoadjuvant or adjuvant therapies. After all definitive therapy ...
Multiple myeloma (MM) remains largely an incurable disease with only a small percentage of patients achieving long-term remission.1 Here, we highlight some of the major studies on MM presented at the American Society of Hematology meeting in December 2021. Monoclonal gammopathy ...
B-cell signalling pathways are critical regulators of B-cell development, expansion, and survival and function via various mediators, including Src family kinases (SFKs), spleen tyrosine kinase, Bruton’s tyrosine kinase (BTK) and phosphatidylinositol 3 kinase (PI3K) (Figure 1).1,2 BTK, a member of ...
Multiple myeloma (MM) is the second most common haematological malignancy, affecting an estimated 450,600 patients worldwide, with an estimated 34,920 new diagnoses and 12,410 patient deaths in the USA in 2021.1,2 Although established curative therapies for MM have not yet been defined, we have ...
Immunoglobulin light chain (AL) amyloidosis is the most common type of systemic amyloidosis, a spectrum of diseases induced by misfolded proteins that generate insoluble amyloid fibrils and deposits in various organs. The precursor protein in AL amyloidosis is a toxic, ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
